Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?

To: Russian Bear who wrote (209)	4/22/1998 4:12:00 PM
From: Steve	Read Replies (2) \| Respond to of 496

In reading the 1st qtr. earnings release I noticed a couple of items which concern me. First, it stated that the lead compound for the neuroimmunophilin program is undergoing additional preclinical research. Does this mean there were some unexpected surprises in the compound? Second, I can't help but notice the substantial decrease in sales from Gliadel from 1997 1st quarter. I can't imagine that this is a good sign given that the 1997 1st quarter was the roll-out quarter (correct me if I'm wrong). I sure hope that Wall Street looks over the Gliadel disappointment to other promising projects.